Opendoor Surges as It’s Re-Added to Russell Indexes
Opendoor jumps after Russell 3000 return news; index buying, retail hype, and improving outlook lift the stock.
Opendoor jumps after Russell 3000 return news; index buying, retail hype, and improving outlook lift the stock.
Biohaven shares rose after strong early results from 2 drugs that quickly lower harmful antibodies in autoimmune diseases.
Vanda’s drug imsidolimab receives orphan drug status in Japan for the rare skin disease GPP, speeding up approval.
IREN signs $1.6B Dell deal for AI hardware, boosting revenue target to $4.4B as it expands data centers by 2027.
Corcept will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback.
New blood test added to cancer screening guidelines makes it easier to check for colorectal cancer, helping more people get tested early.